Cabaletta Bio: Funding, Investors & Team (Oct 2026)
Cabaletta Bio is a biopharmaceutical company that specializes in developing cellular therapies for autoimmune diseases involving B cells. They have created a treatment platform that utilizes CAAR T cells to specifically target and eliminate disease-causing B cells while preserving healthy ones. Cabaletta has partnered with Penn for the exclusive licensing of this technology to treat autoimmune diseases. The company was founded by Dr. Michael Milone, Dr. Aimee Payne, and Dr. Steven Nichtberger, who are also leading scientists at Penn and oversee Cabaletta's research. Their main focus is on developing a treatment for mucosal pemphigus Vulgaris (mPV), a rare autoimmune disease that causes painful blisters and sores on mucous membranes.
Cabaletta Bio has raised $337M across 3 funding rounds on record, the most recent an undisclosed round of $150M announced in May 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cabaletta Bio Company Profile and Key Stats
Latest funding round on record: May 2026.
Cabaletta Bio Funding Rounds
Cabaletta Bio raised $87.0M in an undisclosed round announced in May 2023.
2.1 years later, an undisclosed round of $100M was announced in Jun 2025.
11 months later, an undisclosed round of $150M was announced in May 2026.
Cabaletta Bio Founders and Leadership Team
No contact details are on record for this team yet.
Cabaletta Bio Funding Compared to Other Biotechnology Startups
Cabaletta Bio's latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cabaletta Bio in Biotechnology and Philadelphia
Companies Similar to Cabaletta Bio
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Cabaletta Bio Funding FAQs
What does Cabaletta Bio do?
Cabaletta Bio is a biopharmaceutical company that specializes in developing cellular therapies for autoimmune diseases involving B cells. They have created a treatment platform that utilizes CAAR T cells to specifically target and eliminate disease-causing B cells while preserving healthy ones. Cabaletta has partnered with Penn for the exclusive licensing of this technology to treat autoimmune diseases. The company was founded by Dr. Michael Milone, Dr. Aimee Payne, and Dr. Steven Nichtberger, who are also leading scientists at Penn and oversee Cabaletta's research. Their main focus is on developing a treatment for mucosal pemphigus Vulgaris (mPV), a rare autoimmune disease that causes painful blisters and sores on mucous membranes.
How much funding has Cabaletta Bio raised?
Cabaletta Bio has raised $337M across 3 rounds on record. The most recent is an undisclosed round of $150M announced in May 2026.
When did Cabaletta Bio last raise funding?
Cabaletta Bio's most recent funding round on record is an undisclosed round of $150M, announced in May 2026.
Who founded Cabaletta Bio?
FundedIQ lists Steven Nichtberger (Founder) at Cabaletta Bio.
Where is Cabaletta Bio headquartered?
Cabaletta Bio is based in Philadelphia, Pennsylvania, United States.
How many employees does Cabaletta Bio have?
Cabaletta Bio is in the 101-250 employee band.
How does Cabaletta Bio's funding compare to other Biotechnology startups?
Cabaletta Bio's latest round of $150M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Cabaletta Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cabaletta Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.